Troy A. Luster
0000-0002-7396-0171
Publication & Citation Trends
Publications
0 total
Synthesis of diphenyl-(2-thienyl)phosphine, its chalcogenide derivatives and a series of novel complexes of lanthanide nitrates and triflates.
Cited by 0
Semantic Scholar
Abstract 5574:In vivomodel development for immune cell-based therapeutics
Cited by 0
Semantic Scholar
Epigenetic CRISPR Screens Identify Npm1 as a Therapeutic Vulnerability in Non–Small Cell Lung Cancer OA
Cited by 24
Semantic Scholar
Abstract 5543: TAK1 deficiency in tumor cells enhances sensitivity to CTL-mediated killing via TNF-α
Cited by 0
Semantic Scholar
Selective PET Tracer for Alpha Synucleinopathies: Novel Diagnosis of Parkinson’s Disease (PD), Lewy Body Dementia (LBD), and Multiple System Atrophy (MSA)
Cited by 0
Semantic Scholar
173 An in vivo CRISPR/Cas9 screening platform to identify T cell enhancing edits in distinct solid tumor microenvironments
Cited by 0
Semantic Scholar
In vivo epigenetic CRISPR screen identifies Asf1a as an immunotherapeutic target in Kras-mutant lung adenocarcinoma. OA
Cited by 141
Semantic Scholar
Abstract 4935: High-throughput immune-oncology screen identifies EGFR inhibitors as potent enhancers of CTL antigen-specific tumor cell killing
Cited by 4
Semantic Scholar
Research Topics
RNA modifications and cancer
(47)
MicroRNA in disease regulation
(37)
Extracellular vesicles in disease
(27)
CAR-T cell therapy research
(17)
Cancer Immunotherapy and Biomarkers
(12)
Affiliations
Human Genome Sciences (United States)
Southwestern Medical Center
Dana-Farber Cancer Institute
Intellia Therapeutics (United States)
Center for Cancer Research